Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer

Currently, it is difficult for clinicians to decide which patients will respond to immunotherapy and, therefore, what is the best course of treatment for patients with metastatic renal cell carcinoma (RCC). A recent study published in Oncoimmunology describes a combination of two potential biomarkers that may help predict response to immunotherapy for metastatic RCC patients, […]

read more

Neutrophil-lymphocyte ratio as a prognostic biomarker in high-risk locally advanced kidney cancer

An analysis of the data collected during the S-TRAC study, in which patients with high-risk, localised renal cell carcinoma (RCC) were treated with adjuvant sunitinib (after surgery), showed that sunitinib improved disease-free survival over placebo, but not overall survival. Researchers decided to look at biomarkers for disease-free survival in this study. In this study, a […]

read more

Inflammatory biomarkers to predict outcomes in kidney cancer

There still remains the need for a reliable biomarker to predict outcomes for advanced kidney cancer patients. Scientists have been working hard to try to identify biomarkers that can predict clinical outcomes and the course of the disease in people with metastatic renal cell carcinoma (RCC). A recent study published in Pathology Oncology Research this […]

read more

Potential biomarker to predict outcomes in metastatic kidney cancer

A recent study published in Targeted Oncology last month investigates the role of an enzyme called γ-glutamyltransferase (GGT) as a potential biomarker for metastatic renal cell carcinoma (RCC). High levels of GGT in the blood has been linked with poor survival in various cancers; however, there are no data for metastatic RCC patients. This study […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

ASCO 2020: Biomarkers for immunotherapy treatment for advanced kidney cancer

Biomarkers enable doctors predict which patients will respond to which drugs, and have an important role in many cancers. However, a good biomarker has not yet been found for renal cell carcinoma (RCC). The fundamental issue in the biology of metastatic RCC is that a suitable genetic mutation that ‘drives’ the development of RCC has […]

read more

Diagnostic biomarkers for rare subtype of kidney cancer

There are more than 10 different subtypes of renal cell carcinoma (RCC), each with important genetic differences that determine how aggressive they are or their response to treatment. Clear cell RCC is the most common subtype, accounting for 75-80% of cases. A team of scientists at the University of Michigan, USA, have discovered the gene […]

read more

A potential biomarker for survival for non-metastatic kidney cancer

A recent study published in the journal International Urology and Nephrology this month evaluates mean platelet volume-to-lymphocyte ratio (MPVLR) as a biomarker for survival in patients undergoing nephrectomy for non-metastatic clear cell renal cell carcinoma (ccRCC). In the study, 344 patients with proven ccRCC that has not spread (non-metastatic) were treated with radical or partial […]

read more

C-reactive protein as a potential predictive biomarker for kidney cancer

A recent study published in Science Direct describes how a change in blood C-reactive protein (CRP) levels during the early phase of nivolumab treatment for metastatic renal cell carcinoma (mRCC) may be used to predict survival among patients with mRCC. Read more in Science Direct here

read more

Predictive biomarkers needed for combination treatments in kidney cancer

In this interview with OncLive, Dr Ulka Vaishampayan from Wayne State University in Detroit, USA discusses the immunotherapy combinations that have been approved for first line treatment of metastatic renal cell carcinoma (mRCC) over the past year or so, and the need to identify biomarkers that can guide treatment selection for these patients. The combination […]

read more
Showing 1 to 10 of 61 results
  TOP